0000000001190350
AUTHOR
M Porcu
showing 4 related works from this author
Direct search for light gluinos
1999
We present the results for a direct search for light gluinos through the appearance of $\eta\rightarrow 3\pi^{0}$ with high transverse momentum in the vacuum tank of the NA48 experiment at CERN. We find one event within a lifetime range of $10^{-9}-10^{-3}$s and another one between $10^{-10}-10^{-9}$s. Both events are consistent with the expected background from neutrons in the beam, produced by 450 GeV protons impinging on the Be targets, which interact with the residual air in the tank. From these data we give limits on the production of the hypothetical $g\widetilde{g}$ bound state, the $R^0$ hadron, and its $R^0\rightarrow\eta\widetilde{\gamma}$ decay in the $R^0$ mass range between 1 a…
Modelling the timing of divorce in Italy: a survival analysis on regression quantiles
2011
The analysis of marital dissolution in Italy represents a quite interesting and challenging topic from a substantive standpoint; in fact, despite of the decreasing number of marriages and the increasing number of divorces, the traditional family based on the marriage of heterosexual partners is still considered as a fundamental institution of the society. Here we present a censored quantile regression model with additive terms to investigate the determinants of the timing of marital dissolution on a large and substantial sample from a survey carried on in Italy.
The beam and detector for the NA48 neutral kaon CP violation experiment at CERN
2007
The beam and detector, used for the NA48 experiment, devoted to the measurement of Re (ε{lunate}′ / ε{lunate}), and for the NA48/1 experiment on rare KS and neutral hyperon decays, are described. © 2007 Elsevier B.V. All rights reserved.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
2017
Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…